CA19-9 is a significant prognostic marker of patients with stage III gastric cancer
| Autor: | Yuichiro Yoshioka, Norihiro Yuasa, Yuichi Kambara, Hidemasa Nagai, Hideo Miyake, Soichiro Asai, Koji Shibata |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Multivariate analysis endocrine system diseases CA-19-9 Antigen Adjuvant chemotherapy medicine.medical_treatment Gastroenterology Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Carcinoembryonic antigen Gastrectomy Stomach Neoplasms Internal medicine medicine Biomarkers Tumor Humans Neoplasm Invasiveness Stage (cooking) Aged Neoplasm Staging Aged 80 and over biology business.industry Carcinoma Stage III Gastric Cancer Cancer Margins of Excision General Medicine Middle Aged medicine.disease Prognosis digestive system diseases Carcinoembryonic Antigen Survival Rate Oncology Chemotherapy Adjuvant 030220 oncology & carcinogenesis biology.protein 030211 gastroenterology & hepatology Surgery CA19-9 Female business |
| Zdroj: | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 46(10 Pt) |
| ISSN: | 1532-2157 |
| Popis: | Due to prognostic heterogeneity within a stage of gastric cancer (GC), identification of patients with a high risk for recurrence after resection is important. We aimed to identify the prognostic significance of preoperative serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels in patients with Stage I, II, and III GC who underwent R0 gastrectomy.A total of 794 patients were included in this study after excluding 72 patients with CA19-91.0 U/mL. Receiver operating characteristic curves were drawn to assess the optimal cut-off values of CEA and CA19-9 for disease recurrence.The optimal cut-off values of CEA and CA19-9 levels were 2.9 ng/mL and 46.3 U/mL, respectively. Multivariate analysis for relapse-free survival (RFS) showed that stage of GC, CA19-9 levels, postoperative adjuvant chemotherapy, and venous invasion were significant independent factors. The RFS and overall survival (OS) of patients with CA19-9 ≥ 46.3 U/mL were significantly lower than those with CA19-9 46.3 U/mL in Stage III GC. However, the RFS of GC patients with CA19-9 ≥ 463 U/mL tended to be better than those with CA19-9 levels between 46.3 and 463 U/mL.The RFS and OS of patients with CA19-9 ≥ 46.3 U/mL were significantly lower than those with CA19-946.3 U/mL in Stage III GC. However, there was no value dependency of extremely elevated CA19-9 on RFS. Further risk stratification can be obtained by measuring preoperative serum CA19-9 in stage III GC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect